



**Shield Therapeutics plc**  
("Shield" or the "Company" or the "Group")

**Investor Presentation**

**London, UK – 25 February 2022:** Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on treating iron deficiency with its lead product Accrufer®/Feraccru®, announces that it will provide a live investor presentation on Thursday 3 March 2022 at 4.30pm (GMT).

Chief Executive Officer, Greg Madison will present alongside Chief Financial Officer, Hans-Peter Rudolf and Chief Medical Officer, Dr José Menoyo to provide an update to investors following the recent trading statement. Investors can sign up to Investor Meet Company for free and request to meet Shield Therapeutics plc via the following link: <https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor>

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of regulations and information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. No new price sensitive information will be disclosed, and a PDF of the presentation will be uploaded to the Company's website.

**For further information please contact:**

**Shield Therapeutics plc**

Greg Madison, CEO  
Hans-Peter Rudolf, CFO

[www.shieldtherapeutics.com](http://www.shieldtherapeutics.com)

+44 (0) 191 511 8500

**Nominated Adviser and Joint Broker**

**Peel Hunt LLP**

James Steel/Christopher Golden

+44 (0)20 7418 8900

**Joint Broker**

**finnCap Ltd**

Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks

+44 (0)20 7220 0500

**Financial PR & IR Advisor**

**Walbrook PR**

Lianne Applegarth/Alice Woodings

+44 (0)20 7933 8780 or [shield@walbrookpr.com](mailto:shield@walbrookpr.com)

**Investor Contact (US Advisor)**

LifeSci Advisors, LLC  
John Mullaly

+1 617 429 3548 or [jmullaly@lifesciadvisors.com](mailto:jmullaly@lifesciadvisors.com)

**About Accrufer®/Feraccru®**

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: [www.accrufer.com](http://www.accrufer.com) and [www.feraccru.com](http://www.feraccru.com)

**About Shield Therapeutics plc**

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group